Back to top

Climb Bio initiated with an Outperform at RBC Capital

RBC Capital analyst Nevin Varghese initiated coverage of Climb Bio (CLYM) with an Outperform rating and $23 price target Climb Bio offers an attrac...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Climb Bio, Inc. (CLYM)